These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 29611761)

  • 1. Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: Final report of a 52-week, multicenter postmarketing surveillance study.
    Mimori T; Harigai M; Atsumi T; Fujii T; Kuwana M; Matsuno H; Momohara S; Takei S; Tamura N; Takasaki Y; Yamamoto K; Ikeuchi S; Kushimoto S; Koike T
    Mod Rheumatol; 2019 Mar; 29(2):314-323. PubMed ID: 29611761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in Japan.
    Mimori T; Harigai M; Atsumi T; Fujii T; Kuwana M; Matsuno H; Momohara S; Takei S; Tamura N; Takasaki Y; Ikeuchi S; Kushimoto S; Koike T
    Mod Rheumatol; 2017 Sep; 27(5):755-765. PubMed ID: 27919207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The add-on effectiveness and safety of iguratimod in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab.
    Ebina K; Miyama A; Tsuboi H; Kaneshiro S; Nishikawa M; Owaki H; Tsuji S; Hirao M; Etani Y; Goshima A; Hashimoto J; Yoshikawa H
    Mod Rheumatol; 2019 Jul; 29(4):581-588. PubMed ID: 29882440
    [No Abstract]   [Full Text] [Related]  

  • 4. Factors influencing physician decisions to discontinue treatment after onset of liver dysfunction:
    Ishiguro N; Shibata K; Yoshimura A; Ikeuchi S; Ishii M
    Mod Rheumatol; 2020 Jul; 30(4):633-639. PubMed ID: 31403345
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of iguratimod
    Nozaki Y; Inoue A; Kinoshita K; Funauchi M; Matsumura I
    Mod Rheumatol; 2020 Mar; 30(2):249-258. PubMed ID: 30676812
    [No Abstract]   [Full Text] [Related]  

  • 6. Iguratimod, a synthetic disease modifying anti-rheumatic drug inhibiting the activation of NF-κB and production of RANKL: Its efficacy, radiographic changes, safety and predictors over two years' treatment for Japanese rheumatoid arthritis patients.
    Ishikawa K; Ishikawa J
    Mod Rheumatol; 2019 May; 29(3):418-429. PubMed ID: 29798702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic predictors of efficacy and toxicity of iguratimod in patients with rheumatoid arthritis.
    Xiao W; Guo JP; Li C; Ye H; Wei W; Zou Y; Dai L; Li Z; Zhang M; Li X; Cai X; Zhao J; Wang Y; Tao Y; Liu D; Li Y; Wu M; Sun E; Wu L; Luo L; Mu R; Li Z
    Pharmacogenomics; 2018 Apr; 19(5):383-392. PubMed ID: 29517409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of the clinical use of iguratimod therapy in patients with rheumatoid arthritis.
    Okamura K; Yonemoto Y; Okura C; Kobayashi T; Takagishi K
    Mod Rheumatol; 2015 Mar; 25(2):235-40. PubMed ID: 25065917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iguratimod in combination with methotrexate in active rheumatoid arthritis : Therapeutic effects.
    Xia Z; Lyu J; Hou N; Song L; Li X; Liu H
    Z Rheumatol; 2016 Oct; 75(8):828-833. PubMed ID: 26508503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The three-year efficacy of iguratimod in clinical daily practice in patients with rheumatoid arthritis.
    Suto T; Yonemoto Y; Okamura K; Sakane H; Takeuchi K; Tamura Y; Kaneko T; Ayabe K; Chikuda H
    Mod Rheumatol; 2019 Sep; 29(5):775-781. PubMed ID: 30092680
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical effectiveness of iguratimod based on real-world data of patients with rheumatoid arthritis.
    Mizutani S; Kodera H; Sato Y; Nanki T; Yoshida S; Yasuoka H
    Clin Rheumatol; 2021 Jan; 40(1):123-132. PubMed ID: 32506311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy at 52 weeks of daily clinical use of iguratimod in patients with rheumatoid arthritis.
    Okamura K; Yonemoto Y; Suto T; Okura C; Takagishi K
    Mod Rheumatol; 2015 Jul; 25(4):534-9. PubMed ID: 25529033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pneumocystis jirovecii pneumonia developed in a patient with rheumatoid arthritis after 14 weeks of iguratimod add-on to treatment with methotrexate and etanercept.
    Arita Y; Taguchi H; Kobayashi M; Tono T; Ohsone Y; Okano Y
    Mod Rheumatol; 2018 Nov; 28(6):1041-1043. PubMed ID: 27180974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety study of iguratimod in patients with rheumatoid arthritis.
    Hara M; Abe T; Sugawara S; Mizushima Y; Hoshi K; Irimajiri S; Hashimoto H; Yoshino S; Matsui N; Nobunaga M
    Mod Rheumatol; 2007; 17(1):10-6. PubMed ID: 17278016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: A retrospective study.
    Yoshikawa A; Yoshida S; Kimura Y; Tokai N; Fujiki Y; Kotani T; Matsumura Y; Takeuchi T; Makino S
    Mod Rheumatol; 2018 Mar; 28(2):227-234. PubMed ID: 28644744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iguratimod attenuates general disease activity and improves lung function in rheumatoid arthritis-associated interstitial lung disease patients.
    Shu P; Shao SQ; Cai XN; Zhou DM; Ma H; Lu L; Yin HQ; Yin SL
    Eur Rev Med Pharmacol Sci; 2021 Jul; 25(14):4687-4692. PubMed ID: 34337716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and effectiveness of high-dose methotrexate (over 8 mg/week) in 2838 Japanese patients with rheumatoid arthritis: a postmarketing surveillance report.
    Suzuki Y; Sugiyama N; Fukuma Y; Sugiyama N; Kokubo T
    Mod Rheumatol; 2020 Jan; 30(1):24-35. PubMed ID: 30285533
    [No Abstract]   [Full Text] [Related]  

  • 18. Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis.
    Harigai M; Ishiguro N; Inokuma S; Mimori T; Ryu J; Takei S; Takeuchi T; Tanaka Y; Takasaki Y; Yamanaka H; Watanabe M; Tamada H; Koike T
    Mod Rheumatol; 2016 Jul; 26(4):491-8. PubMed ID: 26635183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients.
    Koike T; Harigai M; Ishiguro N; Inokuma S; Takei S; Takeuchi T; Yamanaka H; Tanaka Y
    Mod Rheumatol; 2012 Aug; 22(4):498-508. PubMed ID: 21993918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting for treatment of patients with active rheumatoid arthritis or ankylosing spondylitis.
    Codreanu C; Šírová K; Jarošová K; Batalov A
    Curr Med Res Opin; 2018 Oct; 34(10):1763-1769. PubMed ID: 29439591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.